BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Addario M, Libermann TA, Xu J, Ahmad A, Menezes J. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways. J Mol Biol 2001;308:501-14. [PMID: 11327783 DOI: 10.1006/jmbi.2001.4589] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Hsiao FC, Lin M, Tai A, Chen G, Huber BT. Cutting Edge: Epstein-Barr Virus Transactivates the HERV-K18 Superantigen by Docking to the Human Complement Receptor 2 (CD21) on Primary B Cells. J Immunol 2006;177:2056-60. [DOI: 10.4049/jimmunol.177.4.2056] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
2 Ohga S, Nomura A, Takada H, Hara T. Immunological aspects of Epstein–Barr virus infection. Critical Reviews in Oncology/Hematology 2002;44:203-15. [DOI: 10.1016/s1040-8428(02)00112-9] [Cited by in Crossref: 46] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
3 Urquiza M, Guevara T, Rodriguez C, Melo-cardenas J, Vanegas M, Patarroyo ME. Decreasing the configurational entropy and the hydrophobicity of EBV-derived peptide 11389 increased its antigenicity, immunogenicity and its ability of inducing IL-6. Amino Acids 2012;42:2165-75. [DOI: 10.1007/s00726-011-0954-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA. Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends Mol Med 2020;26:296-310. [PMID: 31862243 DOI: 10.1016/j.molmed.2019.11.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 14.7] [Reference Citation Analysis]
5 Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol 2007;81:7825-32. [PMID: 17459936 DOI: 10.1128/JVI.00445-07] [Cited by in Crossref: 174] [Cited by in F6Publishing: 126] [Article Influence: 11.6] [Reference Citation Analysis]
6 Huber SA, Rincon M. Coxsackievirus B3 induction of NFAT: requirement for myocarditis susceptibility. Virology 2008;381:155-60. [PMID: 18829062 DOI: 10.1016/j.virol.2008.08.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Chesnokova LS, Jiang R, Hutt-Fletcher LM. Viral Entry. Curr Top Microbiol Immunol 2015;391:221-35. [PMID: 26428376 DOI: 10.1007/978-3-319-22834-1_7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
8 Kato A, Imai K, Sato H, Ogata Y. Prevalence of Epstein-Barr virus DNA and Porphyromonas gingivalis in Japanese peri-implantitis patients. BMC Oral Health 2017;17:148. [PMID: 29233156 DOI: 10.1186/s12903-017-0438-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
9 Marongiu L, Allgayer H. Viruses in colorectal cancer. Mol Oncol 2021. [PMID: 34514694 DOI: 10.1002/1878-0261.13100] [Reference Citation Analysis]
10 MacLeod IJ, Minson T. Binding of herpes simplex virus type-1 virions leads to the induction of intracellular signalling in the absence of virus entry. PLoS One 2010;5:e9560. [PMID: 20221426 DOI: 10.1371/journal.pone.0009560] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
11 Lieberman PM. Keeping it quiet: chromatin control of gammaherpesvirus latency. Nat Rev Microbiol 2013;11:863-75. [PMID: 24192651 DOI: 10.1038/nrmicro3135] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 10.1] [Reference Citation Analysis]
12 Hasler P, Zouali M. Subversion of B lymphocyte signaling by infectious agents. Genes Immun 2003;4:95-103. [DOI: 10.1038/sj.gene.6363941] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
13 Klein SL, Huber S. Sex Differences in Susceptibility to Viral Infection. In: Klein SL, Roberts C, editors. Sex Hormones and Immunity to Infection. Berlin: Springer Berlin Heidelberg; 2010. pp. 93-122. [DOI: 10.1007/978-3-642-02155-8_4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
14 Deng H, Chu JT, Rettig MB, Martinez-maza O, Sun R. Rta of the human herpesvirus 8/Kaposi sarcoma–associated herpesvirus up-regulates human interleukin-6 gene expression. Blood 2002;100:1919-21. [DOI: 10.1182/blood-2002-01-0015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 2.8] [Reference Citation Analysis]
15 Shannon-lowe C, Rowe M. Epstein Barr virus entry; kissing and conjugation. Current Opinion in Virology 2014;4:78-84. [DOI: 10.1016/j.coviro.2013.12.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
16 Schroeter CB, Huntemann N, Bock S, Nelke C, Kremer D, Pfeffer K, Meuth SG, Ruck T. Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells. Front Immunol 2021;12:747143. [PMID: 34691057 DOI: 10.3389/fimmu.2021.747143] [Reference Citation Analysis]
17 Huber S. T cells in coxsackievirus-induced myocarditis. Viral Immunol 2004;17:152-64. [PMID: 15279696 DOI: 10.1089/0882824041310667] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
18 Busse C, Feederle R, Schnölzer M, Behrends U, Mautner J, Delecluse HJ. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding. J Virol 2010;84:1139-47. [PMID: 19889766 DOI: 10.1128/JVI.01953-09] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
19 Urquiza M, Lopez R, Patiño H, Rosas JE, Patarroyo ME. Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells. Journal of Biological Chemistry 2005;280:35598-605. [DOI: 10.1074/jbc.m504544200] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
20 Erdei A, Kovács KG, Nagy-Baló Z, Lukácsi S, Mácsik-Valent B, Kurucz I, Bajtay Z. New aspects in the regulation of human B cell functions by complement receptors CR1, CR2, CR3 and CR4. Immunol Lett 2021;237:42-57. [PMID: 34186155 DOI: 10.1016/j.imlet.2021.06.006] [Reference Citation Analysis]
21 Arredouani MS, Bhasin MK, Sage DR, Dunn LK, Gill MB, Agnani D, Libermann TA, Fingeroth JD. Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection. J Virol 2014;88:5559-77. [PMID: 24600013 DOI: 10.1128/JVI.03099-13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV. The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J Immunol 2009;182:851-9. [PMID: 19124728 DOI: 10.4049/jimmunol.182.2.851] [Cited by in Crossref: 94] [Cited by in F6Publishing: 94] [Article Influence: 7.2] [Reference Citation Analysis]
23 Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 2003;45:1-36. [PMID: 12482570 DOI: 10.1016/S1040-8428(02)00078-1] [Cited by in Crossref: 116] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
24 Harhaj EW, Shembade N. Lymphotropic Viruses: Chronic Inflammation and Induction of Cancers. Biology (Basel) 2020;9:E390. [PMID: 33182552 DOI: 10.3390/biology9110390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Asokan R, Hua J, Young KA, Gould HJ, Hannan JP, Kraus DM, Szakonyi G, Grundy GJ, Chen XS, Crow MK, Holers VM. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus. J Immunol 2006;177:383-94. [PMID: 16785534 DOI: 10.4049/jimmunol.177.1.383] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 3.4] [Reference Citation Analysis]
26 Jangra S, Yuen KS, Botelho MG, Jin DY. Epstein-Barr Virus and Innate Immunity: Friends or Foes? Microorganisms 2019;7:E183. [PMID: 31238570 DOI: 10.3390/microorganisms7060183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
27 Huber S. Cellular Autoimmunity in Myocarditis. Heart Failure Clinics 2005;1:321-31. [DOI: 10.1016/j.hfc.2005.06.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Holers VM, Kulik L. Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation. Mol Immunol 2007;44:64-72. [PMID: 16876864 DOI: 10.1016/j.molimm.2006.07.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
29 Gaudreault E, Fiola S, Olivier M, Gosselin J. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol 2007;81:8016-24. [PMID: 17522215 DOI: 10.1128/JVI.00403-07] [Cited by in Crossref: 86] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
30 Sawada S, Takei M, Inomata H, Nozaki T, Shiraiwa H. What is after cytokine-blocking therapy, a novel therapeutic target--synovial Epstein-Barr virus for rheumatoid arthritis. Autoimmun Rev 2007;6:126-30. [PMID: 17289546 DOI: 10.1016/j.autrev.2006.08.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
31 Chow Y, Chang H, Sia R, Chong P, Sia C. Tonsillar CD4+FOXP3+ T-regulatory cell dynamics in primary EBV infection. Immunol Res 2011;50:97-101. [DOI: 10.1007/s12026-010-8174-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Huang J, Chen H, Hutt-Fletcher L, Ambinder RF, Hayward SD. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 2003;77:13267-74. [PMID: 14645583 DOI: 10.1128/jvi.77.24.13267-13274.2003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
33 Ahmad R, Ennaciri J, Cordeiro P, El Bassam S, Menezes J. Herpes simplex virus-1 up-regulates IL-15 gene expression in monocytic cells through the activation of protein tyrosine kinase and PKC zeta/lambda signaling pathways. J Mol Biol 2007;367:25-35. [PMID: 17239392 DOI: 10.1016/j.jmb.2006.12.060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
34 Asokan R, Banda NK, Szakonyi G, Chen XS, Holers VM. Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE). Mol Immunol 2013;53:99-110. [PMID: 22885687 DOI: 10.1016/j.molimm.2012.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
35 de Lima BD, May JS, Stevenson PG. Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J Virol 2004;78:5103-12. [PMID: 15113892 DOI: 10.1128/jvi.78.10.5103-5112.2004] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]